Logo image of HME.CA

HEMISPHERE ENERGY CORP (HME.CA) Stock Fundamental Analysis

Canada - TSX-V:HME - CA4236301020 - Common Stock

2.02 CAD
-0.14 (-6.48%)
Last: 10/16/2025, 7:00:00 PM
Fundamental Rating

7

Overall HME gets a fundamental rating of 7 out of 10. We evaluated HME against 210 industry peers in the Oil, Gas & Consumable Fuels industry. HME gets an excellent profitability rating and is at the same time showing great financial health properties. HME scores decently on growth, while it is valued quite cheap. This could make an interesting combination. With these ratings, HME could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

HME had positive earnings in the past year.
In the past year HME had a positive cash flow from operations.
Of the past 5 years HME 4 years were profitable.
Each year in the past 5 years HME had a positive operating cash flow.
HME.CA Yearly Net Income VS EBIT VS OCF VS FCFHME.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

1.2 Ratios

Looking at the Return On Assets, with a value of 26.87%, HME belongs to the top of the industry, outperforming 99.05% of the companies in the same industry.
HME has a better Return On Equity (40.34%) than 99.05% of its industry peers.
HME's Return On Invested Capital of 33.61% is amongst the best of the industry. HME outperforms 100.00% of its industry peers.
HME had an Average Return On Invested Capital over the past 3 years of 38.31%. This is significantly above the industry average of 6.85%.
The last Return On Invested Capital (33.61%) for HME is well below the 3 year average (38.31%), which needs to be investigated, but indicates that HME had better years and this may not be a problem.
Industry RankSector Rank
ROA 26.87%
ROE 40.34%
ROIC 33.61%
ROA(3y)27.91%
ROA(5y)18.35%
ROE(3y)41.42%
ROE(5y)28.93%
ROIC(3y)38.31%
ROIC(5y)29.36%
HME.CA Yearly ROA, ROE, ROICHME.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

Looking at the Profit Margin, with a value of 31.38%, HME belongs to the top of the industry, outperforming 87.62% of the companies in the same industry.
In the last couple of years the Profit Margin of HME has grown nicely.
HME has a Operating Margin of 43.33%. This is amongst the best in the industry. HME outperforms 96.19% of its industry peers.
In the last couple of years the Operating Margin of HME has grown nicely.
With a decent Gross Margin value of 60.30%, HME is doing good in the industry, outperforming 78.10% of the companies in the same industry.
In the last couple of years the Gross Margin of HME has remained more or less at the same level.
Industry RankSector Rank
OM 43.33%
PM (TTM) 31.38%
GM 60.3%
OM growth 3Y2.1%
OM growth 5Y4.69%
PM growth 3Y34.16%
PM growth 5Y45.92%
GM growth 3Y-1.38%
GM growth 5Y-1.19%
HME.CA Yearly Profit, Operating, Gross MarginsHME.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), HME is creating value.
Compared to 1 year ago, HME has less shares outstanding
The number of shares outstanding for HME has been increased compared to 5 years ago.
Compared to 1 year ago, HME has an improved debt to assets ratio.
HME.CA Yearly Shares OutstandingHME.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
HME.CA Yearly Total Debt VS Total AssetsHME.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 5.31 indicates that HME is not in any danger for bankruptcy at the moment.
HME has a better Altman-Z score (5.31) than 85.71% of its industry peers.
The Debt to FCF ratio of HME is 0.08, which is an excellent value as it means it would take HME, only 0.08 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.08, HME belongs to the top of the industry, outperforming 95.24% of the companies in the same industry.
A Debt/Equity ratio of 0.03 indicates that HME is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.03, HME is doing good in the industry, outperforming 74.76% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF 0.08
Altman-Z 5.31
ROIC/WACC4.14
WACC8.11%
HME.CA Yearly LT Debt VS Equity VS FCFHME.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

A Current Ratio of 1.62 indicates that HME should not have too much problems paying its short term obligations.
HME has a Current ratio of 1.62. This is in the better half of the industry: HME outperforms 74.76% of its industry peers.
HME has a Quick Ratio of 1.62. This is a normal value and indicates that HME is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of HME (1.62) is better than 75.71% of its industry peers.
Industry RankSector Rank
Current Ratio 1.62
Quick Ratio 1.62
HME.CA Yearly Current Assets VS Current LiabilitesHME.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

4

3. Growth

3.1 Past

HME shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.23%.
HME shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 80.04% yearly.
The Revenue has been growing slightly by 5.28% in the past year.
The Revenue has been growing by 25.97% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)3.23%
EPS 3Y72.84%
EPS 5Y80.04%
EPS Q2Q%-30%
Revenue 1Y (TTM)5.28%
Revenue growth 3Y32.32%
Revenue growth 5Y25.97%
Sales Q2Q%-15.7%

3.2 Future

HME is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -15.87% yearly.
The Revenue is expected to decrease by -7.01% on average over the next years.
EPS Next Y-6.36%
EPS Next 2Y-9.92%
EPS Next 3Y-9.18%
EPS Next 5Y-15.87%
Revenue Next Year-2.08%
Revenue Next 2Y-4.7%
Revenue Next 3Y-4.84%
Revenue Next 5Y-7.01%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
HME.CA Yearly Revenue VS EstimatesHME.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 20M 40M 60M 80M 100M
HME.CA Yearly EPS VS EstimatesHME.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2022 2023 2024 2025 2026 2027 2028 0 0.1 0.2 0.3

8

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 6.31, the valuation of HME can be described as very cheap.
89.05% of the companies in the same industry are more expensive than HME, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.40, HME is valued rather cheaply.
With a Price/Forward Earnings ratio of 7.54, the valuation of HME can be described as very cheap.
Based on the Price/Forward Earnings ratio, HME is valued a bit cheaper than 75.24% of the companies in the same industry.
HME's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.94.
Industry RankSector Rank
PE 6.31
Fwd PE 7.54
HME.CA Price Earnings VS Forward Price EarningsHME.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HME indicates a rather cheap valuation: HME is cheaper than 91.90% of the companies listed in the same industry.
HME's Price/Free Cash Flow ratio is rather cheap when compared to the industry. HME is cheaper than 95.71% of the companies in the same industry.
Industry RankSector Rank
P/FCF 4.74
EV/EBITDA 3.11
HME.CA Per share dataHME.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

HME has an outstanding profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as HME's earnings are expected to decrease with -9.18% in the coming years.
PEG (NY)N/A
PEG (5Y)0.08
EPS Next 2Y-9.92%
EPS Next 3Y-9.18%

5

5. Dividend

5.1 Amount

HME has a Yearly Dividend Yield of 4.55%, which is a nice return.
Compared to an average industry Dividend Yield of 7.51, HME pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.38, HME pays a better dividend.
Industry RankSector Rank
Dividend Yield 4.55%

5.2 History

HME has paid a dividend for less than 5 years, so there is no long track record yet.
Dividend Growth(5Y)N/A
Div Incr Years2
Div Non Decr Years2
HME.CA Yearly Dividends per shareHME.CA Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 0.05 0.1 0.15

5.3 Sustainability

57.92% of the earnings are spent on dividend by HME. This is a bit on the high side, but may be sustainable.
DP57.92%
EPS Next 2Y-9.92%
EPS Next 3Y-9.18%
HME.CA Yearly Income VS Free CF VS DividendHME.CA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M
HME.CA Dividend Payout.HME.CA Dividend Payout, showing the Payout Ratio.HME.CA Dividend Payout.PayoutRetained Earnings

HEMISPHERE ENERGY CORP

TSX-V:HME (10/16/2025, 7:00:00 PM)

2.02

-0.14 (-6.48%)

Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryOil, Gas & Consumable Fuels
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-19 2025-11-19
Inst Owners0.79%
Inst Owner ChangeN/A
Ins Owners15.55%
Ins Owner ChangeN/A
Market Cap191.76M
Analysts84
Price Target2.35 (16.34%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 4.55%
Yearly Dividend0.16
Dividend Growth(5Y)N/A
DP57.92%
Div Incr Years2
Div Non Decr Years2
Ex-Date08-29 2025-08-29 (0.025)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.06%
Min EPS beat(2)-2.91%
Max EPS beat(2)2.8%
EPS beat(4)1
Avg EPS beat(4)-2.76%
Min EPS beat(4)-8.02%
Max EPS beat(4)2.8%
EPS beat(8)3
Avg EPS beat(8)-3.68%
EPS beat(12)6
Avg EPS beat(12)3.66%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)5.19%
Min Revenue beat(2)4.39%
Max Revenue beat(2)5.99%
Revenue beat(4)3
Avg Revenue beat(4)2.23%
Min Revenue beat(4)-2.87%
Max Revenue beat(4)5.99%
Revenue beat(8)6
Avg Revenue beat(8)1.14%
Revenue beat(12)8
Avg Revenue beat(12)-0.62%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)4.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.67%
EPS NY rev (1m)3.45%
EPS NY rev (3m)-16.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.15%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.49%
Valuation
Industry RankSector Rank
PE 6.31
Fwd PE 7.54
P/S 1.88
P/FCF 4.74
P/OCF 3.36
P/B 2.42
P/tB 2.42
EV/EBITDA 3.11
EPS(TTM)0.32
EY15.84%
EPS(NY)0.27
Fwd EY13.26%
FCF(TTM)0.43
FCFY21.11%
OCF(TTM)0.6
OCFY29.78%
SpS1.07
BVpS0.83
TBVpS0.83
PEG (NY)N/A
PEG (5Y)0.08
Profitability
Industry RankSector Rank
ROA 26.87%
ROE 40.34%
ROCE 44.65%
ROIC 33.61%
ROICexc 43.9%
ROICexgc 43.9%
OM 43.33%
PM (TTM) 31.38%
GM 60.3%
FCFM 39.77%
ROA(3y)27.91%
ROA(5y)18.35%
ROE(3y)41.42%
ROE(5y)28.93%
ROIC(3y)38.31%
ROIC(5y)29.36%
ROICexc(3y)41.04%
ROICexc(5y)31.02%
ROICexgc(3y)41.04%
ROICexgc(5y)31.02%
ROCE(3y)50.88%
ROCE(5y)39%
ROICexcg growth 3Y12.92%
ROICexcg growth 5Y20.01%
ROICexc growth 3Y12.92%
ROICexc growth 5Y20.01%
OM growth 3Y2.1%
OM growth 5Y4.69%
PM growth 3Y34.16%
PM growth 5Y45.92%
GM growth 3Y-1.38%
GM growth 5Y-1.19%
F-Score5
Asset Turnover0.86
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF 0.08
Debt/EBITDA 0.04
Cap/Depr 148.25%
Cap/Sales 16.33%
Interest Coverage 250
Cash Conversion 103.23%
Profit Quality 126.75%
Current Ratio 1.62
Quick Ratio 1.62
Altman-Z 5.31
F-Score5
WACC8.11%
ROIC/WACC4.14
Cap/Depr(3y)210.69%
Cap/Depr(5y)187.35%
Cap/Sales(3y)20.24%
Cap/Sales(5y)19.51%
Profit Quality(3y)104.52%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.23%
EPS 3Y72.84%
EPS 5Y80.04%
EPS Q2Q%-30%
EPS Next Y-6.36%
EPS Next 2Y-9.92%
EPS Next 3Y-9.18%
EPS Next 5Y-15.87%
Revenue 1Y (TTM)5.28%
Revenue growth 3Y32.32%
Revenue growth 5Y25.97%
Sales Q2Q%-15.7%
Revenue Next Year-2.08%
Revenue Next 2Y-4.7%
Revenue Next 3Y-4.84%
Revenue Next 5Y-7.01%
EBIT growth 1Y-0.96%
EBIT growth 3Y35.09%
EBIT growth 5Y31.88%
EBIT Next Year34.08%
EBIT Next 3Y-0.98%
EBIT Next 5Y-5.77%
FCF growth 1Y70.97%
FCF growth 3Y57.01%
FCF growth 5YN/A
OCF growth 1Y41.47%
OCF growth 3Y36.33%
OCF growth 5Y34.82%